New paradigms in the management of alloimmune refractoriness to platelet transfusions

Current Opinion in Hematology

Volumn 14, Issue 6, 2007, Pages 655-663

  Vassallo Jr , Ralph R ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b AMERICAN RED CROSS BLOOD SERVICES   (United States)

Author keywords

HLA antibodies; HPA antibodies; Platelet crossmatching; Platelet refractoriness; Platelet transfusion

Indexed keywords

ALLOIMMUNITY; ALLOIMMUNIZATION; BLOOD COMPATIBILITY; BLOOD VOLUME; HLA SYSTEM; HUMAN; LEUKOCYTE COUNT; PREVALENCE; PRIORITY JOURNAL; REVIEW; STATISTICAL SIGNIFICANCE; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION;

ABO BLOOD-GROUP SYSTEM; BLOOD GROUPING AND CROSSMATCHING; FEMALE; HLA ANTIGENS; HUMANS; PLATELET TRANSFUSION; PREGNANCY;

EID: 34848889004     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e3282eec526     Document Type: Review

References (91)

1. Nance ST, Hsu S, Vassallo RR, Murphy S. Review: platelet matching for alloimmunized patients - room for improvement. Immunohematology 2004; 20:80-88.
2. Densmore TL, Goodnough LT, Ali S, et al. Prevalence of HLA sensitization in female apheresis donors. Transfusion 1999; 39:103-106.
3. Taaning E, Simonsen AC, Hjelms E, et al. Platelet alloimmunization after transfusion: a prospective study in 117 heart surgery patients. Vox Sang 1997; 72:238-241.
4. Holohan TV, Terasaki PI, Deisseroth AB. Suppression of transfusion-related alloimmunization in intensively treated cancer patients. Blood 1981; 58:122-128.
5. The Trial to Reduce Alloimmunization to Platelets Study Group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med 1997; 337:1861-1869.
6. Eder AF, Herron R, Strupp A, et al. Transfusion-related acute lung injury surveillance (2003-2005) and the potential impact of the selective use of plasma from male donors in the American Red Cross. Transfusion 2007; 47:599-607. This report describes the incidence and mechanism of transfusion-related acute lung injury, the need to avoid unnecessary plasma transfusion, and efforts to prevent it.
7. Delaflor-Weiss E, Mintz PD. The evaluation and management of platelet refractoriness and alloimmunization. Transfus Med Rev 2000; 14:180-196.
8. Aster RH. Pooling of platelets in the spleen: role in the pathogenesis of 'hypersplenic' thrombocytopenia. J Clin Invest 1966; 45:645-657.
9. Hanson SR, Slichter SS. Platelet kinetics in patients with bone marrow hypoplasia: evidence for a fixed platelet requirement. Blood 1985; 5:1105-1109.
10. Gilcher RO. Apheresis: principles and technology of hemapheresis. In: Simon TL, Dzik WH, Snyder EL, et al., editors. Rossi's principles of transfusion medicine, 3rd ed. Philadelphia, Pennsylvania: Lippincott, Williams, and Wilkins; 2002. pp. 648-658.
11. Sacher RA, Kickler TS, Schiffer CA, et al. Management of patients refractory to platelet transfusion. Arch Pathol Lab Med 2003; 127:409-414.
12. Davis KB, Slichter SJ, Corash L. Corrected count increment and percentage platelet recovery as measures of posttransfusion platelet response: problems and a solution. Transfusion 1999; 39:586-592.
13. O'Connell B, Lee EJ, Schiffer CA. The value of 10-min posttransfusion platelet counts. Transfusion 1988; 28:66-67.
14. Hussein MA, Lee EJ, Schiffer CA. Platelet transfusions administered to patients with splenomegaly. Transfusion 1990; 30:508-510.
15. Bock M, Muggenthaler KH, Schmidt U, Heim MU. Influence of antibiotics on posttransfusion platelet increment. Transfusion 1996; 36:952-954.
16. Bishop JF, McGrath K, Wolf MM, et al. Clinical factors influencing the efficacy of pooled platelet transfusions. Blood 1988; 71:383-387.
17. Bishop JF, Matthews JP, McGrath K, et al. Factors influencing 20-h increments after platelet transfusion. Transfusion 1991; 31:392-396.
18. Alcorta I, Pereira A, Ordinas A. Clinical and laboratory factors associated with platelet transfusion refractoriness: a case-control study. Br J Haematol 1996; 93:220-224.
19. Slichter SJ, Davis K, Enright H, et al. Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood 2005; 105:4106-4114.
20. Friedberg RC, Donnelly SF, Boyd JC, et al. Clinical and blood bank factors in the management of platelet refractoriness and alloimmunization. Blood 1993; 81:3428-3434.
21. Macher S, Schallmoser K, Staber PB, et al. Severe thrombocytopenia due to host-derived anti-HPA-1a after nonmyeloablative allogeneic haematopoietic stem cell transplantation for multiple myeloma: a case report. Vox Sang 2005; 89:257-260.
22. Ertel K, Al-Tawil M, Santoso S, Kroll H. Relevance of the HPA-15 (Gov) polymorphism on CD109 in alloimmune thrombocytopenic syndromes. Transfusion 2005; 45:366-373.
23. Balduini CL, Salvaneschi L, Klersy C, et al. Factors influencing posttransfusional platelet increment in pediatric patients given hematopoietic stem cell transplantation. Leukemia 2001; 15:1885-1891.
24. Kroll H, Kiefel V, Santoso S. Clinical aspects and typing of platelet alloantigens. Vox Sang 1998; 74 (suppl 2):345-354.
25. Cooling L. ABO and platelet transfusion therapy. Immunohematol 2007; 23:20-33. This is a timely, superb review that describes ABO expression on platelets, the impact of ABO compatibility on platelet transfusion, and the potential hazards of plasma-incompatible transfusion.
26. Heal JM, Rowe JM, McMican A, et al. The role of ABO matching in platelet transfusion. Eur J Haematol 1993; 50:110-117.
27. Heal JM, Blumberg N, Masel D. An evaluation of crossmatching, HLA, and ABO matching for platelet transfusions to refractory patients. Blood 1987; 70:23-30.
28. Von Drygalsi A, Curtis BR, Bougie DW, et al. Vancomycin-induced immune thrombocytopenia. New Engl J Med 2007; 356:904-910. This is an authoritative review of the incidence and mechanism behind vancomycin-induced thrombocytopenia, which is important because of the ubiquitous use of the drug in neutropenic individuals.
29. Christie DJ, vanBuren N, Lennon SS, Putnam JL. Vancomycin-dependent antibodies associated with thrombocytopenia and refractoriness to platelet transfusion in patients with leukemia. Blood 1990; 75:518-523.
30. Heal JM, Cowles J, Masel D, et al. Antibodies to plasma proteins: an association with platelet transfusion refractoriness. Br J Haematol 1992; 80:83-90.
31. Daly PA, Schiffer CA, Aisner J, Wiernik PH. Platelet transfusion therapy. One hour posttransfusion increments are valuable in predicting the need for HLA-matched preparations. JAMA 1980; 243:435-438.
32. Doughty HA, Murphy MF, Metcalfe P, et al. Relative importance of immune and nonimmune causes of platelet-refractoriness. Vox Sang 1994; 66:200-205.
33. Aster RH. Effect of anticoagulant and ABO incompatibility on recovery of transfused human platelets. Blood 1965; 26:732-743.
34. Ogasawara K, Ueki J, Takenaka M, Furihata K. Study on the expression of ABH antigens on platelets. Blood 1993; 82:993-999.
35. Brand A, Sintnicolaas K, Claas FHJ, Eernisse JG. ABH antibodies causing platelet transfusion refractoriness. Transfusion 1986; 26:463-466.
36. Skogen B, Rossebo Hansen B, Husebekk A, et al. Minimal expression of blood group A antigen on thrombocytes from A2 individuals. Transfusion 1988; 28:456-459.
37. Lee EJ, Schiffer CA. ABO compatibility can influence the results of platelet transfusion: results of a randomized trial. Transfusion 1989; 29:384-389.
38. Heal JM, Rowe JM, Blumberg N. ABO and platelet transfusion revisited. Ann Hematol 1993; 66:309-314.
39. Heal JM, Masel D, Blumberg N. Interaction of platelet Fc and complement receptors with circulating immune complexes involving the ABO system. Vox Sang 1996; 71:205-211.
40. Heal JM, Masel D, Rowe JM, Blumberg N. Circulating immune complexes involving the ABO system after platelet transfusion. Br J Haematol 1993; 85:566-572.
41. Norol F, Kuentz M, Cordonnier C, et al. Influence of clinical status on the efficiency of stored platelet transfusions. Br J Haematol 1994; 86:125-129.
42. Laundy GJ, Bradley BA, Rees BM, et al. Incidence and specificity of HLA antibodies in multitransfused patients with acquired aplastic anemia. Transfusion 2004; 44:814-825.
43. MacPherson BR, Hammond PB, Maniscalco CA. Alloimmunization to public HLA antigens in multitransfused platelet recipients. Ann Clin Lab Sci 1986; 16:38-44.
44. Rodey GE, Neylan JF, Whelchel JD, et al. Epitope specificity of HLA Class I alloantibodies: I. Frequency analysis of antibodies to private versus public specificities in potential transplant recipients. Hum Immunol 1994; 39:272-280.
45. Howard JE, Perkins HA. The natural history of alloimmunization to platelets. Transfusion 1978; 18:496-503.
46. Dutcher JP, Schiffer CA, Aisner J, Wiernik PH. Long-term follow-up of patients with leukemia receiving platelet transfusions: identification of a large group of patients who do not become alloimmunized. Blood 1981; 58:1007-1011.
47. Lee EJ, Schiffer CA. Serial measurement of lymphocytotoxic antibody and response to nonmatched platelet transfusions in alloimmunized patients. Blood 1987; 70:1727-1729.
48. Godeau B, Fromont P, Seror T, et al. Platelet alloimmunization after multiple transfusions: a prospective study of 50 patients. Br J Haematol 1992; 81:395-400.
49. Kurz M, Greinix H, Hocker P, et al. Specificities of antiplatelet antibodies in multitransfused patients with haemato-oncological disorders. Br J Haematol 1996; 95:564-569.
50. Uhrynowska M, Zupanska B. Platelet-specific antibodies in transfused patients. Eur J Haematol 1996; 56:248-251.
51. Sanz C, Freire C, Alcorta I, et al. Platelet-specific antibodies in HLA-immunized patients receiving chronic platelet support. Transfusion 2001; 41:762-765.
52. Kiefel V, Konig C, Kroll H, Santoso S. Platelet alloantibodies in transfused patients. Transfusion 2001; 41:766-770.
53. Duquesnoy RJ, Marrari M. Multilaboratory evaluation of serum analysis for HLA antibody and crossmatch reactivity by lymphocytotoxicity methods. Results of the American Society for Histocompatibility and Immunogenetics/College of American Pathologists proficiency testing surveys during 1993-2000. Arch Pathol Lab Med 2003; 127:149-156.
54. Zeevi A, Girnita A, Duquesnoy R. HLA antibody analysis: sensitivity, specificity and clinical significance in solid organ transplantation. Immunol Res 2006; 36:255-264.
55. Colombo MB, Haworth SE, Poli F, et al. Luminex technology for anti-HLA antibody screening: evaluation of performance and of impact on laboratory routine. Cytometry B Clin Cytom 2007; Mar 30 [Epub ahead of print]. This paper is important reading for laboratory personnel contemplating a switch to Luminex-based HLA class I antibody detection.
56. El-Awar N, Lee J, Terasaki PI. HLA antibody identification with single antigen beads compared to conventional methods. Hum Immunol 2005; 66:989-997.
57. Saidman SL. Histocompatibility testing for highly sensitized transplant candidates. Transplant Proc 2007; 39:673-675. A recent brief review of HLA antibody identification technology is presented.
58. Moses LA, Stroncek DF, Cipolone KM, Marincola FM. Detection of HLA antibodies by using flow cytometry and latex beads coated with HLA antigens. Transfusion 2000; 40:861-866.
59. Worthington JE, Robson AJ, Sheldon S, et al. A comparison of enzyme-linked immunoabsorbent assays and flow cytometry techniques for the detection of HLA specific antibodies. Hum Immunol 2001; 62:1178-1184.
60. Anonymous. Detection of platelet-reactive antibodies in patients who are refractory to platelet transfusions, and the selection of compatible donors. Vox Sang 2003; 84:73-88.
61. Lown JAG, Ivey JG. Evaluation of a solid phase red cell adherence technique for platelet antibody screening. Transfus Med 1991; 1:163-167.
62. Pei R, Lee JH, Shih NJ, et al. Single human leukocyte antigen flow cytometry beads for accurate identification of human leukocyte antigen antibody specificities. Transplantation 2003; 75:43-49.
63. Lucas DP, Paparounis ML, Myers L, et al. Detection of HLA Class I-specific antibodies by the QuikScreen enzyme-linked immunosorbent assay. Clin Diag Lab Immunol 1997; 4:252-257.
64. Levin MD, de Veld JC, van der Holt B, van'tVeer MB. Screening for alloantibodies in the serum of patients receiving platelet transfusions: a comparison of the ELISA, lymphocytotoxicity, and the indirect immunofluorescence method. Transfusion 2003; 43:72-77.
65. Lubenko A, Rodi KM, Johnson AC. Screening for WBC antibodies by lymphocyte indirect immunofluorescence flow cytometry: superior to cytotoxicity and ELISA? Transfusion 2001; 41:1147-1153.
66. Kurz M, Knobl P, Kahls P, et al. Platelet-reactive HLA antibodies associated with low posttransfusion platelet increments: a comparison between the monoclonal antibody-specific immobilization of platelet antigens assay and the lymphocytotoxicity test. Transfusion 2001; 41:771-774.
67. Kiefel V. The MAIPA assay and its applications in immunohaematology. Transfus Med 1992; 2:181-188.
68. Lucas GF, Rogers SE. Evaluation of an enzyme-linked immunosorbent assay kit (GTI PakPlus) for the detection of antibodies against human platelet antigens. Transfus Med 1999; 9:63-67.
69. Saito S, Ota S, Seshimo H, et al. Platelet transfusion refractoriness caused by a mismatch in HLA-C antigens. Transfusion 2002; 42:302-308.
70. Cano P, Klitz W, Mack SJ, et al. Common and well documented HLA alleles: report of the ad-hoc committee of the American Society for Histocompatibility and Immunogenetics. Hum Immunol 2007; 68:392-417. This is the most recent listing of known HLA class I alleles and their serologic equivalents.
71. Schiffer CA, Keller C, Dutcher JP, et al. Potential HLA-matched platelet donor availability for alloimmunized patients. Transfusion 1983; 23:286-289.
72. King KE, Ness PM, Braine HE, Armstrong KS. Racial differences in the availability of leukocyte antigen-matched platelets. J Clin Apher 1996; 11:71-77.
73. Duquesnoy RJ, Filip DJ, Rodey GE, et al. Successful transfusion of platelets 'mismatched' for HLA antigens to alloimmunized thrombocytopenic patients. Am J Hematol 1977; 2:219-226.
74. Hussain MA, Lee EJ, Fletcher R, Schiffer CA. The effect of lymphocytotoxic antibody reactivity on the results of single antigen mismatched platelet transfusions to alloimmunized patients. Blood 1996; 87:3959-3962.
75. Dahlke MB, Weiss KL. Platelet transfusions from donors mismatched for crossreactive HLA antigens. Transfusion 1984; 24:299-302.
76. MacPherson BR. HLA antibody formation within the HLA-A1 crossreactive group in multitransfused platelet recipients.Am J Hematol 1989; 30:228-232.
77. Duquesnoy RJ, Filip DJ, Aster RH. Influence of HLA-A2 on the effectiveness of platelet transfusions in alloimmunized thrombocytopenic patients. Blood 1977; 50:407-412.
78. Nambiar A, Duquesnoy RJ, Adams S, et al. HLAMatchmaker-driven analysis of responses to HLA-typed platelet transfusions in alloimmunized thrombocytopenic patients. Blood 2006; 107:1680-1687. This fascinating new predictive tool can assist in the choice of HLA-selected products. This program can be downloaded from the University of Pittsburgh website (http://tpis.upmc. edu).
79. Duquesnoy RJ, Vieira J, Aster RH. Donor availability for platelet transfusion support of alloimmunized thrombocytopenic patients. Transplant Proc 1977; 9:519-521.
80. Moroff G, Garratty G, Heal JM, et al. Selection of platelets for refractory patients by HLA matching and prospective crossmatching. Transfusion 1992; 32:633-640.
81. Rachel JM, Sinor LT, Tawfik OW, et al. A solid-phase red cell adherence test for platelet cross-matching. Med Lab Sci 1985; 42:194-195.
82. O'Connell BA, Schiffer CA. Donor selection for alloimmunized patients by platelet crossmatching of random-donor platelet concentrates. Transfusion 1990; 30:314-317.
83. Rachel JM, Summers TC, Sinor LT, Plapp FV. Use of a solid phase red blood cell adherence method for pretransfusion platelet compatibility testing. Am J Clin Pathol 1988; 90:63-68.
84. Petz LD. The HLA system and platelet transfusion. In: Murphy S, editor. The HLA system: basic biology and clinical applications. Bethesda, MD: American Association of Blood Banks; 1999. pp. 133-175.
85. Petz LD, Garratty G, Calhoun L, et al. Selecting donors of platelets for refractory patients on the basis of HLA antibody specificity. Transfusion 2000; 40:1446-1456.
86. Murphy S, Varma M. Selecting platelets for transfusion of the alloimmunized patient: a review. Immunohematology 1998; 14:117-123.
87. Schiffer CA, O'Connell B, Lee EJ. Platelet transfusion therapy for alloimmunized patients: selective mismatching for HLA B12, an antigen with variable expression on platelets. Blood 1989; 74:1172-1176.
88. Aster RH, Szatkowski N, Liebert M, Duquesnoy RJ. Expression of HLA-B12, HLA-B8, Bw4 and w6 on platelets. Transplant Proc 1977; 9:1695-1696.
89. Szatkowski NS, Aster RH. HLA antigens of platelets. IV. Influence of "private" HLA-B locus specificities on the expression of Bw4 and Bw6 on human platelets. Tissue Antigens 1980; 15:361-368.
90. Novotny VMJ. Prevention and management of platelet transfusion refractoriness. Vox Sang 1999; 76:1-13.
91. Vieira CA, Agarwal A, Book BK, et al. Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics and pharmacokinetics. Transplantation 2004; 77:542-548.